Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 11, 2009, Pages 5217-5225

  Li, Zhongqiu ^a,b   van Bergen, Tine ^a   van de Veire, Sara ^a,c   van de Vel, Isabelle ^a   Moreau, Huberte ^d   Dewerchin, Mieke ^e   Maudgal, Prabhat C ^c   Zeyen, Thierry ^c   Spileers, Werner ^a,c   Moons, Lieve ^f   Stalmans, Ingeborg ^a,c  

^a Laboratory of Ophthalmology   (Belgium)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d ThromboGenics NV   (Belgium)

^e DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^f UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN 189; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; EXPERIMENTAL RABBIT; FEMALE; FIBROBLAST; FILTERING OPERATION; GENE EXPRESSION; GLAUCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOLOGY; INTRAOCULAR PRESSURE; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCAR; SCAR FORMATION; TRABECULECTOMY; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTERIOR CHAMBER; ANTIBODIES, MONOCLONAL; AQUEOUS HUMOR; CELL PROLIFERATION; CELLS, CULTURED; CICATRIX; CONJUNCTIVAL DISEASES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; GLAUCOMA, OPEN-ANGLE; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; POSTOPERATIVE COMPLICATIONS; RABBITS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TONOMETRY, OCULAR; TRABECULECTOMY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77950535778     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2662     Document Type: Article

References (56)

1. Burr J, Azuara-Blanco A, Avenell A. Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst Rev. 2005;18(2):CD004399.
2. Hitchings R. Initial treatment for open-angle glaucoma-medical, laser, or surgical? Surgery is the treatment of choice for open-angle glaucoma. Arch Ophthalmol. 1998;116(2):241-242.
3. Lama PJ, Fechtner RD. Antifibrotic and wound healing in glaucoma surgery. Surv Ophthalmol. 2003;48(3):314-346.
4. Addicks EM, Quigley HA, Green WR, Robin AL. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol. 1983;101(5):795-798.
5. Roth A, Muhlendyck H, De Gottrau P. [The function of Tenon's capsule revisited]. J Fr Ophthalmol. 2002;25(9):968-976.
6. Cordeiro MF, Bhattacharya S, Schultz GS, Khaw PT. TGF-α1, -α2 and -α3 in vitro: biphasic effects on Tenon's fibroblasts contraction, proliferation and migration. Invest Ophthalmol Vis Sci. 2000; 41(3):756-763.
7. Cordeiro M, Mead A, Ali RR, et al. Novel antisense oligonucleotides targeting TGF-α inhibit in vivo scarring and improved surgical outcome. Gene Ther. 2003;10(1):59-71.
8. Cordeiro M, Gay JA, Khaw T. Human anti-transforming growth factor-2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci. 1999;40(10):2225-2234.
9. CAT-152 0102 Trabeculectomy Study Group, Khaw P, Grehn F, et al. A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology. 2007; 114(10):1822-1830.
10. Charnock-Jones DS. Vascular endothelial growth factors (VEGFs), their receptors and their inhibition. Cell Transmissions. The Newsletter for Cell Signaling and Neuroscience Research. 2005;21(1): 1-5.
11. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380(6573):435-439.
12. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res. 2006; 12(17):5018-5022.
13. Kakehashi A, Inoda S, Mameuda C et al. Relationship among VEGF, VEGF receptor, AGEs, and macrophages in proliferative diabetic retinopathy. Diabetes Res Clin Pract. 2008;79(3):438-445.
14. Tripathi RC, Li J, Tripathi B, et al. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105(2):232-237.
15. Kozawa T, Sone H, Okuda Y, et al. Vascular endothelial growth factor levels in the aqueous and serum in diabetic retinopathy with or without neovascular glaucoma. Nippon Ganka Gakkai Zasshi. 1998;102(11):731-738.
16. Vinores SA, Chan CC, Vinores MA, et al. Increased vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-α) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization. J Neuroimmunol. 1998; 89(1-2):43-50.
17. Frank RN. Growth factors in age-related macular degeneration: pathogenic and therapeutic implications. Ophthalmic Res. 1997; 29(5):341-353.
18. Murakami M, Iwai S, Hiratsuka S, et al. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood. 2006;108(6):1849-1856.
19. Beddy D, Watson RW, Fitzpatrick JM, O'Connell PR. Increased vascular endothelial growth factor production in fibroblasts isolated from strictures in patients with Crohn's disease. Br J Surg. 2004;91(1):72-77.
20. Wilgus TA, Ferreira AM, Oberyszyn TM, Bergdall VK, DiPietro LA. Regulation of scar formation by vascular endothelial growth factor. Lab Invest. 2008;88(6):579-590.
21. Jakeman LB, Winer J, Bennett GL, Altar CA, Ferrara N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest. 1992;89(1):244-253.
22. Robinson GS, Ju M, Shih SC, et al. Nonvascular role for VEGF: VEGFR-1,-2 activity is critical for neural retinal development. FASEB J. 2001;15(7):1215-1217.
23. Kim I, Ryan AM, Rohan R. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci. 1999;40(9):2115-2121.
24. Yasuhara T, Shingo T, Date I. The potential role of vascular endothelial growth factor in the central nervous system. Rev Neurosci. 2004;15(4):293-307.
25. Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 1995;15(7):4738-4747.
26. Pertvaara L, Kaipainen A, Mustonen T, et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem. 1994; 269(9):6271-6274.
27. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res. 1994;59(6):723-727.
28. Midgley R, Kerr D. Bevacizumab-current status and future directions. Ann Oncol. 2005;16(7):999-1004.
29. Marty M, Pivot X. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur J Cancer. 2008;44(7):912-920.
30. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90(11):1344-1349.
31. Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley MA. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina. 2006; 26(8):882-888.
32. Esson DW, Popp MP, Liu L, et al. Microarray analysis of the failure of filtering blebs in a rat model of glaucoma filtering surgery. Invest Ophthalmol Vis Sci. 2004;45(12):4450-4462.
33. Cordeiro MF, Constable PH, Alexander RA, Bhattacharya SS, Khaw PT. Effect of varying the mitomycin-C treatment area in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci. 1997; 38(8):1639-1646.
34. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7(5):575-583.
35. Wells AP, Crowston JG, Marks J, et al. A pilot study of a system for grading of drainage blebs after glaucoma surgery. J Glaucoma. 2004;13(6):454-460.
36. Kinnunen K, Korpisalo P, Rissanen TT, et al. Overexpression of VEGF-A induces neovascularization and increased vascular leakage in rabbit eye after intravitreal adenoviral gene transfer. Acta Physiol (Oxford). 2006;187(4):447-457.
37. Hitchings RA, Grierson I. Clinico pathological correlation in eyes with failed fistulizing surgery. Trans Ophthalmol Soc UK. 1983; 103(Pt1):84-88.
38. The Fluorouracil Filtering Surgery Study Group. Fluorouracil Filtering Surgery Study one-year follow-up. Am J Ophthalmol. 1989; 108(6):625-635.
39. The Fluorouracil Filtering Surgery Study Group. Five-year follow- up of the Fluorouracil Filtering Surgery Study. Am J Ophthalmol. 1996;121(4):349-366.
40. Weinreb RN. Riding the Trojan horse of glaucoma surgery. J Glaucoma. 1995;4:2-4.
41. Knapp A, Heuer DK, Stern GA, Driebe WT Jr. Serious corneal complications of glaucoma filtering surgery with postoperative 5-fluorouracil. Am J Ophthalmol. 1987;103(2):183-187.
42. Shapiro MS, Thoft RA, Friend J, et al. 5-Fluorouracil toxicity to the ocular surface epithelium. Invest Ophthalmol Vis Sci. 1985;26(4): 580-583.
43. Dellaporta A. Fundus changes in postoperative hypotony. Am J Ophthalmol. 1955;40(6):781-785.
44. Soltau JB, Rothman RF, Budenz DL, et al. Risk factors for glaucoma filtering bleb infections. Arch Ophthalmol. 2000; 118(3):338-342.
45. Greenfield DS, Liebmann JM, Jee J, et al. Late-onset bleb leaks after glaucoma filtering surgery. Arch Ophthalmol. 1998;116(4):443-447.
46. Colwell AS, Beanes SR, Soo C, et al. Increased angiogenesis and expression of vascular endothelial growth factor during scarless repair. Plast Reconstr Surg. 2005;115(1):204-212.
47. Hu DN, Ritch R, Liebmann D, et al. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma. 2002;11(5):406-410.
48. Aeillo LP, Avery RL, Arigg PG, et al. Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-1487.
49. Flammer J. Vascular risk factors in glaucoma. Klin Monatsbl Augenheilkd. 1997;211(4): aA5-aA6.
50. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114(5):855-859.
51. Miller MH, Joseph NH, Ennis KW, et al. An animal model of filtration surgery. Trans Ophthalmol Soc UK. 1985;104(8):893-897.
52. Schultz G, Khaw PT, Oxford K, et al. Growth factors and ocular wound healing. Eye. 1994;8(Pt 2):184-197.
53. Tahery MM, Lee DA. Pharmacologic control of wound healing in glaucoma. J Ocul Pharmacol. 1989;5(2):155-179.
54. Li WW, Li WV, Tsakayannis D, et al. Angiogenesis in wound healing. Contemporary Surgery (supplement). 2003;Nov: 4-11.
55. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol. 1998;152(6):1445-1452.
56. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007;131(3):463-475.